UTHR stock forecast, quote, news & analysis
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs... Show more
Why United Therapeutics (UTHR) Is Up +17% in the Last 30 Days
Key Takeaways
- UTHR stock surged +17% over the past 30 days, driven by positive Phase 3 TETON-1 trial results for Tyvaso in idiopathic pulmonary fibrosis (IPF), triggering a 12.5% single-day gain.
- Over the past quarter, shares rose +18%, supported by strong Q4 earnings beat, ADVANCE OUTCOMES study success for ralinepag in pulmonary arterial hypertension (PAH), and a $2 billion share repurchase authorization.
- Analyst upgrades and raised price targets from firms like TD Cowen and Cantor Fitzgerald reflect optimism around pipeline expansions and robust Tyvaso sales growth.
- Key products like Tyvaso and Orenitram continue to fuel revenue, with the company targeting a $4 billion revenue run rate by 2027.
- Positive clinical data across IPF and PAH indications positions UTHR for potential label expansions and new market opportunities.
United Therapeutics (UTHR) Company Overview and Market Position
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing innovative therapies for chronic and life-threatening diseases, primarily in the pulmonary space. Its core business revolves around products addressing pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), including Tyvaso (treprostinil inhalation solution), Orenitram (oral treprostinil), Remodulin, and Adcirca.
The company operates in the competitive biotech sector, with a strong foothold in PAH treatments where it holds significant market share. Its business model emphasizes proprietary delivery technologies like inhaled and oral formulations of treprostinil, providing steady revenue from high-margin specialty drugs. Recent stock price movement aligns with expanding indications for Tyvaso beyond PAH into IPF, bolstering long-term growth prospects amid favorable fundamentals like high profit margins exceeding 40%.
United Therapeutics (UTHR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, UTHR stock climbed +17%, from approximately $504 (late February close) to around $588. The movement was volatile and trend-driven, with a sharp 12.5% jump on March 30 following TETON-1 data release, building on prior gains from clinical and buyback news.
For the past quarter, shares advanced +18%, from $497 (early January) to $588. Performance featured steady uptrend punctuated by catalysts, reaching a 52-week high near $608, reflecting strong momentum in the biotech sector stock analysis.
What Drove UTHR Stock Price in the Last 30 Days
The primary catalyst was the March 30 announcement of positive TETON-1 Phase 3 results, where nebulized Tyvaso met its primary endpoint of improved forced vital capacity (FVC) by 130.1 mL in IPF patients (p<0.0001), surpassing TETON-2 outcomes. This drove a 12.5% surge on high volume, as it supports a planned FDA supplemental application by summer end.
Analyst reactions included TD Cowen raising its target to $660 (Buy), Cantor Fitzgerald to $625 (Overweight), and others, signaling 15-25% upside potential. Earlier, the March 9 $2 billion share repurchase (with $1.5 billion ASR) underscored confidence, boosting sentiment. These factors overshadowed minor insider sales, focusing market attention on pipeline validation and capital returns.
What Drove UTHR Stock Performance Over the Last Quarter
The quarter's +18% gain stemmed from sustained positive narratives, starting with February Q4 earnings: EPS $7.70 beat estimates by $0.94, revenue $790 million up 7% (despite slight miss), driven by Tyvaso DPI adoption.
March 2 ADVANCE OUTCOMES Phase 3 success for ralinepag showed 55% reduced clinical worsening risk in PAH (HR 0.45, p<0.0001), enhancing its oral prostacyclin profile. The $2 billion buyback added tailwinds, while analyst upgrades (e.g., UBS to $705) reflected institutional buying and sector tailwinds in biotech amid improving macro conditions. Cumulative impact highlighted UTHR's competitive edge in pulmonary therapies.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, which analyze and trade thousands of tickers across various strategies, timeframes, and performance metrics like win rate, profit factor, and drawdown. These curated bots represent the most relevant and successful ones based on recent market conditions, offering users insights into automated trading approaches from short-term scalping to long-term trend following. Whether focusing on momentum, mean reversion, or sector-specific plays, the page highlights bots with proven track records. Explore Trending AI Robots to discover tools that could enhance your stock analysis and trading decisions.
UTHR Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming FDA interactions for Tyvaso IPF label expansion post-TETON data, full ADVANCE OUTCOMES presentation, and ralinepag NDA submission in H2 2026. Q1 earnings will provide updates on Tyvaso sales and guidance toward $4 billion run-rate. Broader industry trends in PAH/IPF treatments, macro factors like interest rates affecting biotech valuations, and share repurchase execution could sway sentiment. Risks include regulatory delays, trial data details at conferences like ATS in May, and competitive dynamics; catalysts may arise from partnerships or new pipeline readouts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Aroon Indicator for UTHR shows an upward move is likely
UTHR's Aroon Indicator triggered a bullish signal on April 09, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 260 similar instances where the Aroon Indicator showed a similar pattern. In of the 260 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on April 16, 2026. You may want to consider a long position or call options on UTHR as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UTHR advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for UTHR moved out of overbought territory on April 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for UTHR turned negative on April 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTHR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
UTHR broke above its upper Bollinger Band on March 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. UTHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.632) is normal, around the industry mean (29.176). P/E Ratio (21.113) is within average values for comparable stocks, (64.302). Projected Growth (PEG Ratio) (2.344) is also within normal values, averaging (2.071). UTHR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (8.850) is also within normal values, averaging (110.511).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsGeneric